| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| tau Proteins | 22 | 2019 | 208 | 4.080 |
Why?
|
| Neurodegenerative Diseases | 11 | 2016 | 251 | 1.890 |
Why?
|
| Drosophila Proteins | 12 | 2016 | 723 | 1.870 |
Why?
|
| Primary Health Care | 5 | 2023 | 772 | 1.860 |
Why?
|
| Drosophila melanogaster | 12 | 2016 | 771 | 1.840 |
Why?
|
| Parkinson Disease | 8 | 2017 | 694 | 1.340 |
Why?
|
| Tauopathies | 6 | 2014 | 62 | 1.270 |
Why?
|
| Physician Assistants | 3 | 2020 | 66 | 1.250 |
Why?
|
| alpha-Synuclein | 7 | 2018 | 124 | 1.230 |
Why?
|
| Drosophila | 13 | 2017 | 781 | 1.170 |
Why?
|
| Disease Models, Animal | 16 | 2016 | 4355 | 0.960 |
Why?
|
| Alzheimer Disease | 12 | 2019 | 787 | 0.930 |
Why?
|
| Eye | 7 | 2016 | 227 | 0.860 |
Why?
|
| Genes, Modifier | 2 | 2012 | 11 | 0.790 |
Why?
|
| Evidence-Based Practice | 2 | 2020 | 114 | 0.780 |
Why?
|
| Continuity of Patient Care | 1 | 2023 | 154 | 0.730 |
Why?
|
| Essential Tremor | 2 | 2022 | 89 | 0.690 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2013 | 146 | 0.670 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 606 | 0.660 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 354 | 0.650 |
Why?
|
| Nerve Degeneration | 5 | 2009 | 126 | 0.640 |
Why?
|
| Peptides | 5 | 2011 | 793 | 0.620 |
Why?
|
| Glycogen Synthase Kinase 3 | 5 | 2011 | 64 | 0.610 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 44 | 0.610 |
Why?
|
| Animals, Genetically Modified | 11 | 2016 | 315 | 0.600 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 94 | 0.590 |
Why?
|
| Aging | 4 | 2016 | 1184 | 0.590 |
Why?
|
| Handwriting | 1 | 2017 | 8 | 0.570 |
Why?
|
| Resistance Training | 1 | 2017 | 32 | 0.550 |
Why?
|
| Quality of Health Care | 4 | 2023 | 389 | 0.550 |
Why?
|
| Home Care Services | 1 | 2017 | 68 | 0.540 |
Why?
|
| Preventive Health Services | 1 | 2017 | 58 | 0.530 |
Why?
|
| Disease Management | 2 | 2019 | 519 | 0.520 |
Why?
|
| United States Department of Veterans Affairs | 7 | 2019 | 668 | 0.520 |
Why?
|
| Genetic Testing | 3 | 2012 | 1004 | 0.500 |
Why?
|
| Patients | 1 | 2016 | 121 | 0.500 |
Why?
|
| Animals | 38 | 2019 | 34154 | 0.480 |
Why?
|
| Electronic Health Records | 1 | 2022 | 722 | 0.480 |
Why?
|
| Neurofibrillary Tangles | 4 | 2014 | 26 | 0.460 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2017 | 255 | 0.450 |
Why?
|
| Pigmentation | 2 | 2012 | 35 | 0.450 |
Why?
|
| Chorea | 1 | 2014 | 39 | 0.450 |
Why?
|
| Genomics | 2 | 2012 | 1486 | 0.440 |
Why?
|
| Gait | 1 | 2015 | 146 | 0.440 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 355 | 0.440 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 2055 | 0.430 |
Why?
|
| Autophagy | 2 | 2014 | 395 | 0.430 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 356 | 0.430 |
Why?
|
| Humans | 61 | 2023 | 124311 | 0.430 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 397 | 0.420 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 577 | 0.410 |
Why?
|
| Neuroglia | 1 | 2014 | 202 | 0.410 |
Why?
|
| Memory Disorders | 1 | 2014 | 238 | 0.400 |
Why?
|
| Research Design | 1 | 2016 | 686 | 0.400 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2014 | 160 | 0.390 |
Why?
|
| Retinal Photoreceptor Cell Inner Segment | 1 | 2011 | 4 | 0.390 |
Why?
|
| Memory | 2 | 2014 | 363 | 0.390 |
Why?
|
| Amyloid beta-Peptides | 5 | 2019 | 210 | 0.380 |
Why?
|
| Huntington Disease | 3 | 2010 | 143 | 0.380 |
Why?
|
| Phosphorylation | 9 | 2014 | 1626 | 0.370 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 853 | 0.360 |
Why?
|
| Patient Care Team | 3 | 2022 | 545 | 0.360 |
Why?
|
| Visual Fields | 1 | 2011 | 133 | 0.360 |
Why?
|
| Immunotherapy | 3 | 2011 | 662 | 0.350 |
Why?
|
| Aminopeptidases | 2 | 2006 | 19 | 0.340 |
Why?
|
| Protein Multimerization | 5 | 2013 | 128 | 0.340 |
Why?
|
| Vision Disorders | 1 | 2011 | 211 | 0.330 |
Why?
|
| Movement Disorders | 2 | 2009 | 222 | 0.330 |
Why?
|
| Mutation | 9 | 2014 | 5806 | 0.330 |
Why?
|
| Neurons | 5 | 2016 | 1971 | 0.320 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 156 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2008 | 11 | 0.310 |
Why?
|
| Specialization | 1 | 2009 | 75 | 0.310 |
Why?
|
| Dopamine | 2 | 2009 | 285 | 0.310 |
Why?
|
| Aged | 15 | 2023 | 19456 | 0.310 |
Why?
|
| Models, Genetic | 2 | 2016 | 759 | 0.300 |
Why?
|
| Medicine | 1 | 2009 | 97 | 0.300 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2009 | 356 | 0.290 |
Why?
|
| Hypertension | 1 | 2016 | 1282 | 0.290 |
Why?
|
| Neurology | 1 | 2009 | 108 | 0.290 |
Why?
|
| Genes, Dominant | 1 | 2008 | 247 | 0.290 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1604 | 0.280 |
Why?
|
| Amyloidosis | 3 | 2011 | 67 | 0.260 |
Why?
|
| Skin Diseases | 3 | 2011 | 124 | 0.250 |
Why?
|
| Frontal Lobe | 3 | 2015 | 111 | 0.250 |
Why?
|
| Middle Aged | 13 | 2019 | 26428 | 0.250 |
Why?
|
| Brain | 6 | 2014 | 3005 | 0.240 |
Why?
|
| Lewy Body Disease | 2 | 2015 | 18 | 0.230 |
Why?
|
| Colorectal Neoplasms | 3 | 2016 | 566 | 0.230 |
Why?
|
| Male | 20 | 2020 | 60976 | 0.230 |
Why?
|
| Pastoral Care | 2 | 2014 | 3 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2009 | 518 | 0.220 |
Why?
|
| United States | 9 | 2023 | 10757 | 0.210 |
Why?
|
| Female | 19 | 2020 | 66248 | 0.210 |
Why?
|
| Quality Improvement | 3 | 2023 | 638 | 0.210 |
Why?
|
| Inappropriate Prescribing | 1 | 2023 | 41 | 0.210 |
Why?
|
| Glycerol | 2 | 2013 | 92 | 0.200 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2011 | 58 | 0.200 |
Why?
|
| Amyloid | 3 | 2011 | 65 | 0.200 |
Why?
|
| Cell Death | 3 | 2016 | 240 | 0.200 |
Why?
|
| Insect Proteins | 1 | 2002 | 99 | 0.190 |
Why?
|
| Photoreceptor Cells, Invertebrate | 1 | 2002 | 60 | 0.190 |
Why?
|
| Hospitals, Veterans | 2 | 2014 | 355 | 0.190 |
Why?
|
| Eye Abnormalities | 1 | 2002 | 106 | 0.190 |
Why?
|
| Trans-Activators | 2 | 2002 | 808 | 0.180 |
Why?
|
| Mental Health Services | 2 | 2014 | 255 | 0.180 |
Why?
|
| Mutation, Missense | 3 | 2013 | 868 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 228 | 0.180 |
Why?
|
| Nervous System Malformations | 1 | 2002 | 130 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1530 | 0.180 |
Why?
|
| Iron Chelating Agents | 1 | 2019 | 14 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 2019 | 161 | 0.150 |
Why?
|
| Phenotype | 4 | 2016 | 4257 | 0.150 |
Why?
|
| Antibodies | 4 | 2015 | 372 | 0.150 |
Why?
|
| Protein Binding | 2 | 2014 | 1748 | 0.140 |
Why?
|
| Hand Strength | 1 | 2017 | 41 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2017 | 44 | 0.140 |
Why?
|
| Iron | 1 | 2019 | 267 | 0.140 |
Why?
|
| Eligibility Determination | 1 | 2017 | 37 | 0.140 |
Why?
|
| Health Personnel | 1 | 2022 | 505 | 0.140 |
Why?
|
| Motor Skills | 1 | 2017 | 83 | 0.140 |
Why?
|
| Glycerol Kinase | 2 | 2013 | 19 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 492 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
| Incidental Findings | 1 | 2017 | 124 | 0.130 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2016 | 51 | 0.130 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1686 | 0.130 |
Why?
|
| Proteins | 3 | 2006 | 1043 | 0.130 |
Why?
|
| Age Factors | 2 | 2016 | 2804 | 0.130 |
Why?
|
| Life Style | 1 | 2018 | 410 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 560 | 0.120 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2016 | 49 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 174 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 171 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2011 | 623 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 448 | 0.120 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 13 | 0.120 |
Why?
|
| Exercise Test | 1 | 2015 | 248 | 0.120 |
Why?
|
| RNA Interference | 2 | 2013 | 503 | 0.120 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2014 | 29 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 3342 | 0.110 |
Why?
|
| Retina | 2 | 2016 | 454 | 0.110 |
Why?
|
| Transgenes | 2 | 2008 | 336 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2017 | 762 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2016 | 749 | 0.110 |
Why?
|
| Comprehensive Health Care | 1 | 2014 | 18 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2016 | 257 | 0.110 |
Why?
|
| Imaginal Discs | 1 | 2013 | 11 | 0.110 |
Why?
|
| Medication Errors | 1 | 2016 | 184 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 3726 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 2014 | 120 | 0.110 |
Why?
|
| RNA | 1 | 2017 | 568 | 0.110 |
Why?
|
| Veterans | 5 | 2016 | 1751 | 0.110 |
Why?
|
| Health Behavior | 1 | 2016 | 383 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 688 | 0.110 |
Why?
|
| United States Department of Defense | 1 | 2013 | 10 | 0.110 |
Why?
|
| Heart Rate | 1 | 2015 | 588 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2014 | 178 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 2534 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 775 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1267 | 0.100 |
Why?
|
| Apoptosis | 2 | 2014 | 1790 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 221 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2014 | 215 | 0.100 |
Why?
|
| Biopolymers | 1 | 2012 | 20 | 0.100 |
Why?
|
| Retinal Photoreceptor Cell Outer Segment | 1 | 2011 | 7 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2002 | 2607 | 0.100 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 2012 | 36 | 0.100 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 10 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2011 | 13 | 0.100 |
Why?
|
| Mice | 10 | 2014 | 17740 | 0.100 |
Why?
|
| Dark Adaptation | 1 | 2011 | 38 | 0.100 |
Why?
|
| Contrast Sensitivity | 1 | 2011 | 59 | 0.100 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 26 | 0.100 |
Why?
|
| Visual Field Tests | 1 | 2011 | 48 | 0.100 |
Why?
|
| Amyloidogenic Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Adult | 4 | 2016 | 29357 | 0.090 |
Why?
|
| Biological Assay | 1 | 2012 | 100 | 0.090 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 2414 | 0.090 |
Why?
|
| Neurotoxins | 1 | 2011 | 56 | 0.090 |
Why?
|
| Rats | 3 | 2013 | 3690 | 0.090 |
Why?
|
| Osteitis Deformans | 1 | 2011 | 7 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 112 | 0.090 |
Why?
|
| Myositis, Inclusion Body | 1 | 2011 | 8 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 130 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 143 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2011 | 117 | 0.090 |
Why?
|
| Proteostasis Deficiencies | 1 | 2010 | 5 | 0.090 |
Why?
|
| Frontotemporal Dementia | 1 | 2011 | 43 | 0.090 |
Why?
|
| Genes, Lethal | 2 | 2013 | 76 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 476 | 0.090 |
Why?
|
| Exercise | 1 | 2016 | 820 | 0.090 |
Why?
|
| Young Adult | 2 | 2016 | 8972 | 0.090 |
Why?
|
| Genotype | 2 | 2014 | 2551 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2015 | 1322 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 286 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2012 | 183 | 0.080 |
Why?
|
| Alzheimer Vaccines | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 455 | 0.080 |
Why?
|
| Repetitive Sequences, Amino Acid | 2 | 2006 | 19 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2087 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 6467 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 354 | 0.080 |
Why?
|
| In Situ Hybridization | 2 | 2006 | 471 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 428 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1887 | 0.080 |
Why?
|
| Immunization | 1 | 2010 | 307 | 0.080 |
Why?
|
| Microtubules | 1 | 2008 | 197 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 816 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 127 | 0.070 |
Why?
|
| Huntingtin Protein | 2 | 2004 | 63 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 1115 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2013 | 763 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2011 | 814 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 1272 | 0.070 |
Why?
|
| Hippocampus | 1 | 2012 | 832 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 645 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2010 | 383 | 0.070 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 98 | 0.070 |
Why?
|
| Computational Biology | 1 | 2011 | 818 | 0.070 |
Why?
|
| Cell Count | 1 | 2007 | 252 | 0.070 |
Why?
|
| Blotting, Northern | 1 | 2006 | 259 | 0.070 |
Why?
|
| Exons | 2 | 2008 | 796 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1207 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 457 | 0.060 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2004 | 11 | 0.060 |
Why?
|
| Trinucleotide Repeats | 1 | 2005 | 110 | 0.060 |
Why?
|
| Biomarkers | 1 | 2014 | 2976 | 0.060 |
Why?
|
| Vaccines | 1 | 2010 | 369 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2004 | 134 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 395 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2006 | 1109 | 0.060 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 384 | 0.060 |
Why?
|
| Caspases | 1 | 2004 | 162 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 822 | 0.050 |
Why?
|
| Dementia | 1 | 2008 | 450 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1015 | 0.050 |
Why?
|
| Gene Expression | 1 | 2008 | 1569 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2008 | 1024 | 0.050 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2002 | 6 | 0.050 |
Why?
|
| Armadillo Domain Proteins | 1 | 2002 | 9 | 0.050 |
Why?
|
| Primidone | 1 | 2022 | 9 | 0.050 |
Why?
|
| High Mobility Group Proteins | 1 | 2002 | 32 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 45 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 1392 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 162 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2002 | 118 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1241 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 129 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2001 | 75 | 0.050 |
Why?
|
| beta Catenin | 1 | 2002 | 206 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 268 | 0.040 |
Why?
|
| Glutamine | 1 | 2001 | 210 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2002 | 821 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2012 | 833 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2613 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1693 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 276 | 0.040 |
Why?
|
| Neuroblastoma | 2 | 2014 | 520 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 964 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 579 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 1410 | 0.040 |
Why?
|
| Adolescent | 1 | 2016 | 19350 | 0.040 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 604 | 0.040 |
Why?
|
| Microelectrodes | 1 | 2016 | 42 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 1459 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 121 | 0.030 |
Why?
|
| Electroretinography | 1 | 2016 | 114 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 58 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2008 | 4534 | 0.030 |
Why?
|
| Vision, Ocular | 1 | 2016 | 122 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1101 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 103 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2016 | 304 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 199 | 0.030 |
Why?
|
| Clergy | 1 | 2014 | 4 | 0.030 |
Why?
|
| Prions | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cellular Structures | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2015 | 102 | 0.030 |
Why?
|
| Myelin Basic Protein | 1 | 2014 | 69 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2016 | 195 | 0.030 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 199 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 755 | 0.030 |
Why?
|
| Wings, Animal | 1 | 2013 | 32 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 220 | 0.030 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 16 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 64 | 0.030 |
Why?
|
| Larva | 1 | 2013 | 248 | 0.030 |
Why?
|
| Health Surveys | 1 | 2014 | 243 | 0.030 |
Why?
|
| Solutions | 1 | 2012 | 65 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 57 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 124 | 0.030 |
Why?
|
| Hypoadrenocorticism, Familial | 1 | 2012 | 2 | 0.020 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2012 | 37 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 131 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2011 | 11 | 0.020 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2011 | 31 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 371 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2012 | 64 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 2012 | 80 | 0.020 |
Why?
|
| Hematoxylin | 1 | 2011 | 8 | 0.020 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2011 | 9 | 0.020 |
Why?
|
| Congo Red | 1 | 2011 | 7 | 0.020 |
Why?
|
| Birefringence | 1 | 2011 | 11 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2011 | 10 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 61 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2011 | 30 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2014 | 340 | 0.020 |
Why?
|
| Dermis | 1 | 2011 | 24 | 0.020 |
Why?
|
| Valosin Containing Protein | 1 | 2011 | 6 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 4425 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 225 | 0.020 |
Why?
|
| Epidermis | 1 | 2011 | 60 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2012 | 164 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 174 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2011 | 79 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 202 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 660 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 117 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2010 | 31 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2010 | 15 | 0.020 |
Why?
|
| Thiazoles | 1 | 2011 | 97 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 46 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 187 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Protein Folding | 1 | 2011 | 218 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 16223 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 239 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1415 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 152 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2011 | 142 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2010 | 75 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1231 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2011 | 208 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 508 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2010 | 180 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1017 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2013 | 544 | 0.020 |
Why?
|
| Endopeptidase K | 1 | 2009 | 4 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2870 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 460 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1612 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2009 | 34 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 196 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2009 | 93 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2009 | 91 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3085 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1089 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2038 | 0.020 |
Why?
|
| Introns | 1 | 2008 | 300 | 0.020 |
Why?
|
| Macrophages | 1 | 2011 | 618 | 0.020 |
Why?
|
| Puromycin | 1 | 2006 | 11 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2020 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 1069 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 1237 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 890 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 606 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 788 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 1614 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 1129 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1181 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 98 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 568 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3415 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 2771 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2009 | 939 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 276 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 1341 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 466 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2005 | 179 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1321 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 309 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 464 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 1950 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 657 | 0.010 |
Why?
|
| Fetal Development | 1 | 2005 | 131 | 0.010 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2001 | 5 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2001 | 26 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 63 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2001 | 90 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2001 | 52 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3267 | 0.010 |
Why?
|
| Acetylation | 1 | 2001 | 175 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 153 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2001 | 114 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2699 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2001 | 313 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 3093 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3873 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2824 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12279 | 0.010 |
Why?
|
| Histones | 1 | 2001 | 534 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 3134 | 0.010 |
Why?
|